< Back to previous page
Researcher
Anna Sablina
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
- See also: Anna Sablina (Flanders Institute for Biotechnology)
Affiliations
- Laboratory for Mechanisms of Cell Transformation (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - Laboratory for Mechanisms of Cell Transformation (VIB-KU Leuven) (Division)
Member
From1 Jan 2017 → Today - Sablina Lab (Research group)
Responsible
From1 Jan 2017 → Today - Department of Human Genetics (Department)
Member
From16 Apr 2009 → 31 Dec 2016
Projects
1 - 10 of 20
- Molecular structure and pharmacological activation of LZTR1 towards novel anticancer therapiesFrom20 Aug 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Mapping the functional role of the low copy repeats in the phenotypic variability of the 22q11.2 Deletion SyndromeFrom27 Jan 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Optimize single -cell sequence approaches in PDACFrom14 Nov 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Micropeptides as novel biomarkers and precision medicine targets in cancerFrom26 Sep 2022 → 26 Jan 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Micropeptides in head and neck cancerFrom9 Nov 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Targeting KRAS proteoastasis to develop personalized therapies for lung cancer patientsFrom1 Oct 2021 → TodayFunding: Foundations, funds and other with scientific goal
- Micropeptides as potential targets for cancer treatment in Lung AdenocarcinomaFrom18 Nov 2020 → 1 Jun 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- The role of LZTR1 in cancer development and progressionFrom10 Apr 2020 → 10 Apr 2024Funding: Own budget, for example: patrimony, inscription fees, gifts
- Alterations in RAS interactome triggered by ubiquitinationFrom1 Dec 2019 → 1 Dec 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Nanobody-based approach to inhibit RAS activity by modultating its interactomeFrom1 Jan 2019 → 31 Dec 2022Funding: Foundations, funds and other with scientific goal
Publications
31 - 40 of 50
- Cancer-associated chromosomal deletions: Size makes a difference(2016)
Authors: Yanyan Cai, Anna Sablina
Pages: 2850 - 2851 - Loss of Chromosome 8p Governs Tumor Progression and Drug Response by Altering Lipid Metabolism(2016)
Authors: Yanyan Cai, Jonathan Crowther, Maria Francesca Baietti, Ali Talebi, Fabrizio Renzi, Jonas Dehairs, Johan Swinnen, Anna Sablina
Pages: 751 - 766 - The role of protein tyrosine phosphatase receptor type 0(PTPRO) in colon cancer(2016)
Authors: Layka Abbasi Asbagh, Sabine Tejpar, Anna Sablina
Number of pages: 104 - OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination(2016)
Authors: Maria Francesca Baietti, Jonathan Crowther, Anna Sablina
Pages: 288 - 303 - Therapeutic relevance of the protein phosphatase 2A in cancer(2016)
Authors: Anna Sablina
Pages: 61544 - 61561 - Nuclear p16INK4a expression predicts enhanced radiation response in head and neck cancers(2016)
Authors: Rüveyda Dok, Anna Sablina, Sandra Nuyts
Pages: 38785 - 38795 - Unraveling and targeting radiotherapy response in HPV related head and neck cancers(2015)
Authors: Rüveyda Dok, Sandra Nuyts, Anna Sablina
- Retraction to: The role of specific PP2A complexes in the dephosphorylation of γH2AX [J. Cell Sci. doi: 10.1242/jcs.147223](2015)
Authors: L Chen, Y Lai, X Zhu, L Ma, Q Bai, I Vazquez, Y Xiao, C Liu, D Li, C Gao, et al.
Pages: 421 - The role of specific PP2A complexes in the dephosphorylation of γ-H2AX(2015)
Authors: Anna Sablina
Pages: 421 - The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling(2014)
Authors: Loredana Vecchione, Maria Francesca Baietti, Pascale Zimmermann, Anna Sablina, Sabine Tejpar
Pages: 10070 - 10083